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ABSTRACT 
 
Background 
AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We 
performed a multi-histology basket study of AZD5363, an ATP-competitive pan-AKT kinase 
inhibitor, to determine the efficacy of AKT inhibition in AKT mutant cancers.  
 
Methods 
Fifty-eight patients with AKT1-mutant solid tumors were treated. Key end points included 
response rate, progression-free survival (PFS), and safety. Tumor biopsies and plasma cell-
free DNA (cfDNA) were collected in the majority of patients with the goal of identifying 
predictive biomarkers of drug response. 
 
Results 
In heavily pretreated patients with AKT1 E17K mutant tumors (median lines of systemic 
therapy=5), the median PFS was 5.5 (95% CI 2.9-6.9), 6.6 (1.5-8.3), and 4.2 (2.1-12.8) 
months in the ER+ breast, gynecologic, and other solid tumor cohorts, respectively. 
Imbalance of the AKT1 E17K mutant allele, mostly frequently caused by loss of the 
remaining wildtype allele, was associated with longer PFS (hazard ratio [HR]=0.41, p=0.04), 
as was the presence of coincident PI3K pathway hotspot mutations (HR=0.21, p=0.045). 
Persistent declines in AKT1 E17K in cfDNA were associated with improved PFS (HR=0.18, 
p=0.004) and response (p=0.025). Clinical benefit was not restricted to patients with 
detectable AKT1 E17K in pretreatment cfDNA or patients with clonal AKT E17K mutations. 
The most common grade ≥3 adverse events were hyperglycemia (24%), diarrhea (17%) and 
rash (15.5%). 
 
Conclusions 
This study provides the first clinical data that AKT1 E17K is a therapeutic target in human 
cancer. The genomic context of the AKT1 E17K mutation further conditioned response to 
AZD5363. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT01226316) 
 
  
INTRODUCTION 
 
Phosphoinositide 3-kinase (PI3K)/AKT is among the most frequently activated pathways in 
cancer.1,2 Activation can occur through mutation of multiple signaling nodes including PTEN, 
PIK3R1, PIK3CA, AKT, and mTOR.3-5 Clinical development of drugs targeting this pathway 
has focused primarily on inhibitors of PI3K isoforms and mTOR.6-8 The AKT kinase family 
includes three structurally related serine-threonine kinases that serve as critical downstream 
effectors of PI3 kinase signaling. Large-scale genomic profiling of human cancers has 
identified gain-of-function mutations in AKT1 in a broad range of tumor types with AKT1 
E17K being, by far, the most frequent hotspot.9-14 This mutation promotes pathological 
localization of AKT1 to the plasma membrane, thereby stimulating constitutive downstream 
signaling.15  
 
AKT inhibitors have been in clinical testing for several years, but have not been specifically 
tested in AKT1-mutant tumors. Testing these inhibitors in AKT1-mutant patients using 
traditional clinical trial designs is challenging because, unlike many other oncogenes, AKT1 
E17K is infrequent in all individual tumor lineages. To determine whether AKT1-mutant 
cancers are sensitive to direct AKT inhibition and whether tumor lineage influenced drug 
sensitivity, we performed a multi-cohort basket study of the orally administered pan-AKT 
inhibitor AZD536316 in patients with AKT1-mutant solid tumors. Tumor biopsies and analyses 
of tumor-derived DNA in plasma were performed to identify genomic determinants of drug 
response and to guide future combination studies. 
 
METHODS 
 
Study Oversight 
The study was designed by AstraZeneca with the principal investigators and conducted in 
accordance with the provision of the Declaration of Helsinki and Good Clinical Practice 
guidelines. Institutional review boards at each center approved the protocol. 
 
Patients 
Eligible patients had histologically confirmed advanced solid tumors, refractory to standard 
therapies, no prior exposure to catalytic AKT inhibitors, and tumors harboring AKT1 
mutations but no known concurrent RAS/RAF mutations as determined by local tumor 
testing. Complete eligibility criteria are available in the Supplementary Appendix. Written 
informed consent was obtained for all participants. 
 
Study Design, Treatment, and Endpoints 
This was a multi-cohort basket study of patients with solid tumors harboring AKT1 mutations. 
The phase I component of this study has been presented previously and defined the safety, 
optimal dose and schedule of AZD5363, and its efficacy in patients with PIK3CA 
mutations.17,18 Here, patients were enrolled to one of three cohorts: estrogen receptor-
positive (ER+) breast cancer, gynecologic cancers, and all other solid tumors and treated on 
a 21-day cycle of 480 mg AZD5363 twice daily for four days followed by three days off, 
repeated weekly. Key end points included investigator-assessed response according to 
RECIST version 1.1, PFS, and safety. In some cases, ER+ breast or endometrial cancer 
patients with progression on AZD5363 monotherapy were permitted to crossover to the 
combination of AZD5363 and fulvestrant, a selective estrogen receptor antagonist and 
degrader, at the approved dose regardless of prior fulvestrant exposure, based on preclinical 
data suggesting synergy with the combination.19 Patient-level clinical data are available in 
Table S1. 
 
Assessments 
Disease assessments with CT or MRI were performed at baseline, every 6 weeks for 6 
months, and then every 12 weeks until disease progression, death, or withdrawal. Adverse 
events were graded by the investigator according to the CTCAE, version 4.0 until day 28 
after discontinuation of study treatment. 
 
Biomarker Studies 
Tumor tissue samples and tumor-derived cell free (cf) DNA in plasma were collected for 
biomarker studies. Next-generation sequencing was performed utilizing both targeted and 
whole-exome sequencing on pre-treatment DNA from formalin-fixed paraffin embedded 
tumor and matched blood specimens (Table S3).20,21 Droplet digital polymerase-chain-
reaction analysis (ddPCR) using an allele-specific assay was performed on cfDNA from pre-
treatment and longitudinally collected plasma samples. Complete sequencing and data 
analysis methods are described in the Supplementary Appendix. 
 
Statistical Analysis 
Interim analysis was planned following enrollment of 20 patients to each cohort. Efficacy and 
safety analyses included all patients receiving at least one dose of AZD5363 with the 
exception of one patient with an AKT1-wildtype tumor who was mistakenly enrolled and was 
thus excluded from the efficacy analyses. PFS was assessed using Kaplan-Meier methods. 
Statistical analyses were conducted on a data cut taken on May 31, 2016. 
 
RESULTS 
 
Patients, Efficacy, and Safety 
Fifty-eight patients with AKT1-mutant solid tumors (52 E17K, 6 non-E17K) were treated 
(Table 1). Patients were heavily pretreated (median prior regimens=5). In total, 73% (38/52) 
of AKT1 E17K patients achieved some regression of target lesions including confirmed 
partial responses according to RECIST in ER+ breast and endometrial cancers (n=4 and 2, 
respectively) as well as cervix cancer, triple negative breast cancer, and lung 
adenocarcinoma (n=1 each) (Fig. 1). Additional unconfirmed partial responses occurred in 
ER+ breast cancer (n=2), triple negative breast cancer (n=1), and anal adenocarcinoma 
(n=1). In AKT1 non-E17K patients, tumor regressions not meeting response criteria were 
observed in two AKT1 Q79K-mutant patients (prostate and ovarian), including one lasting 14 
months. Median PFS (with 95% CI) in the AKT1 E17K mutant ER+ breast, gynecologic, and 
other solid cancer cohorts was 5.5 months (2.9-6.9), 6.6 months (1.5-8.3), and 4.2 months 
(2.1-12.8), respectively. There was no apparent relationship between tumor type and 
likelihood of response. Six patients (5 ER+ breast and 1 endometrial) crossed over to 
AZD5363 plus fulvestrant after progression on AZD5363 monotherapy. None achieved an 
objective response, but one ER+ breast cancer patient who was previously fulvestrant-
resistant had a durable tumor regression. 
 
The most common grade ≥3 adverse events were hyperglycemia (24%), diarrhea (17%), 
and maculopapular rash (15.5%) (Table 2). Overall, 34% of patients required a dose 
reduction with diarrhea, maculopapular rash, and hyperglycemia being the most common 
indications. AZD5363 was permanently discontinued in 12% of patients due to adverse 
events. Drug-related serious adverse events occurred in 15.5% of patients and were 
consistent with the overall side-effect profile of AZD5363 (Table S2).  
 
Non-Invasive Monitoring of Circulating Biomarker in cfDNA 
As patients were enrolled on the basis of local archival tumor sequencing, we sought to 
determine the presence of AKT1 E17K in cfDNA from plasma collected at the time of 
enrollment. Notably, AKT1 E17K was detected in pre-treatment plasma by ddPCR in only 
81.4% (35/43) of patients with evaluable samples (Fig. 1). Among patients with undetectable 
AKT1 E17K in cfDNA (n=8), archival tumor was available for central sequencing in six 
patients and confirmed the presence of the E17K mutation in five. Two of these patients had 
partial responses and a third patient had a durable tumor regression lasting over 8 months. 
Broader analysis of plasma from these three patients using a capture-based cfDNA assay 
also identified no tumor-derived mutations. The only patient where AKT1 E17K could not be 
confirmed in either cfDNA or in archival tumor progressed rapidly. 
 
To determine whether tumor-derived cfDNA could be utilized as an early surrogate of drug 
response and to explore the dynamics of the circulating biomarker under the selective 
pressure of AKT inhibition, longitudinal plasma samples were tested in 23 patients (Fig. 2A). 
A decrease in AKT1 E17K mutant allele fraction of ≥50% from baseline during cycle 1 was 
observed in 95.5% (22/23) of patients but did not correlate with outcome (Fig. 2B). 
Conversely, persistent decreases maintained into cycle 2 were associated with longer PFS 
when compared with patients in whom cfDNA decreases were not achieved or did not 
persist (median PFS 5.6 versus 2.6 months, respectively, hazard ratio=0.18, p=0.004, Fig. 
2C). Progression by cfDNA, defined as a rise in the circulating AKT1 E17K mutant allele 
fraction of ≥50% above nadir, preceded radiographic progression in all but one patient by a 
median of 42 days (95% CI: 31-68 days) (Fig. 2D). Longitudinal profiling of cfDNA during 
treatment also captured fluctuations in disease burden, including re-sensitization to 
AZD5363 following addition of fulvestrant in one ER+ breast cancer patient. This fulvestrant-
resistant patient achieved a durable tumor regression (-22%) lasting 8 months after crossing 
over to combined AZD5363 and fulvestrant therapy, the duration of which matched or 
exceeded that previously achieved with either agent alone (Fig. 2E). Broader next-
generation sequencing of pretreatment cfDNA in this patient captured the complete 
mutational profile of genetically heterogeneous individual tumor sites (Fig. 2F).  
 
Genomic correlates of response to AKT inhibition 
To determine whether the genomic configuration of AKT1 (number of mutant and wildtype 
copies) or co-incident tumor mutations influenced AZD5363 response, we performed whole 
exome or targeted sequencing of archival and fresh pre-treatment tumors in a subset of 
patients. In the 37 patients with adequate material for this analysis, 57% (21/37) exhibited 
allelic imbalance of the AKT1 E17K mutation. Here, the frequency of the E17K allele was 
higher than expected for a heterozygous oncogenic mutation and higher than the allele 
frequency of other clonal somatic mutations in the corresponding tumors (Fig. 3A). This 
finding could not be explained by focal amplification of the E17K allele, which was present in 
only two tumors. To determine the etiology of this allelic imbalance, we performed allele-
specific copy number analysis of the sequencing data, which revealed that 48% (10/21) of 
cases had copy-neutral loss-of-heterozygosity (CN-LOH). This duplication of the mutant 
AKT1 allele with concomitant loss of the remaining wild-type copy ultimately resulted in two 
mutant AKT1 E17K copies and no wildtype copies (Fig.3B, Fig. S1-S2). CN-LOH arose in 
molecular time shortly after acquisition of the E17K mutation and, in some patients, was 
followed by genomic gains of the locus. Notably, patients whose tumors exhibited allelic 
imbalance of AKT1 E17K had a longer PFS than those without it with a median PFS of 8.2 
versus 4.1 months, respectively (HR=0.41, p=0.04, Fig. 3C). In the study cohort, AKT1 E17K 
allelic imbalance was associated with tumor lineage, arising more commonly in breast and 
gynecological cancers compared to all others enrolled (90 versus 10% respectively) (Fig. 1).  
 
We also explored how clonality of the AKT1 E17K mutation influenced AZD5363 response. 
In total, 92% (34/37) of patients had clonal (present in all tumor cells) AKT1 mutations (Fig. 
3A). Two of the three patients with subclonal AKT1 E17K mutations had rapid disease 
progression. The third patient, with ovarian granulosa cell cancer, had a mixed response 
with an overall tumor regression of 24% lasting 253 days (Fig. 3D). To understand the basis 
of this clinical benefit despite the presence of a subclonal AKT1 E17K mutation, we 
sequenced 9 metastatic sites sampled prior to the initiation of AZD5363 treatment (Fig. 3E) 
and found that while the AKT1 mutation was subclonal across the lesions, the resected right 
pelvic tumor that subsequently recurred and achieved the best response (-42.5%) had the 
highest cellular fraction (67% of cancer cells) of the AKT1 E17K mutation (Fig. 3E). These 
results suggest that later acquisition of AKT1 E17K driver mutations may not entirely 
preclude response to AZD5363. 
 
Leveraging the broader-based sequenced we performed here, we explored whether 
particular co-mutations were associated with intrinsic sensitivity or resistance to AKT 
inhibition. Notably, five patients had coincident activating mutations in either up- or 
downstream effectors of PI3K/mTOR signaling. The presence of coincident PI3K pathway 
alterations was associated with improved PFS compared to those without (median not 
reached versus 4.3 months, HR=0.21, p=0.045). Importantly, concurrently mutated genes 
that would be expected to activate parallel signaling pathways did not necessarily preclude 
response to AZD5363. Two of five patients with loss-of-function NF1 mutations (cervix and 
breast cancer) achieved durable partial responses, one of which also had a subclonal 
FGFR3 S249C hotspot mutation. In a non-responding colorectal cancer patient, a subclonal 
KRAS A146T hotspot mutation not detected by local tumor profiling was identified in 
pretreatment cfDNA, a mutation which pre-clinically is associated with resistance to 
AZD5363.16 Mutational hotspots in the ligand binding domain of ESR1, which are associated 
with acquired resistance to endocrine therapy and poor prognosis22, were identified in 
metastatic tumor tissue or cfDNA in 35% (7/20) of ER+ breast cancer patients and were 
associated with a shorter median PFS compared to those without (p=0.02; Fig. 1 and Fig. 
S3). 
 
DISCUSSION 
 
This study provides the first clinical evidence that AKT1 E17K is a targetable oncogene in 
human cancer. Treatment with AZD5363 yielded durable responses and tumor regressions 
across a variety of tumor types harboring the mutation including breast (ER+ and triple 
negative), endometrial, cervix, and lung cancers. 
 
The breadth and depth of pretreatment sequencing data available allowed us to explore how 
different facets of these patients’ tumors further conditioned response to AKT inhibition. We 
unexpectedly found that tumors harboring AKT1 E17K mutations frequently exhibit selection 
against the remaining wildtype allele, most often due to duplication of the mutant allele via 
CN-LOH, resulting in allelic imbalance. This genomic configuration, surprising for an 
oncogene, appears to be both allele and lineage-specific as it was enriched in AKT1 E17K-
mutant breast and endometrial cancers, but not observed in other tumor lineages or affecting 
other driver mutations involving the PI3K and MAPK pathways (Fig. S2). This AKT1 E17K 
allelic imbalance was associated with a statistically and clinically significant improvement in 
PFS. This finding suggests that classifying genomic biomarkers as simply present or absent 
may overlook additional informative factors, such as genomic configuration, that are relevant 
to patient selection and lineage dependence. Similarly, we found that while two patients with 
tumors bearing subclonal AKT1 mutations did not respond to AZD5363, one granulosa cell 
cancer patient with extensive intratumoral heterogeneity had durable tumor regression at 
disease sites harboring the highest cellular fraction of AKT1 E17K. This finding suggests that 
limiting targeted therapy to patients only with clonal AKT1 mutations may not be entirely 
appropriate. 
 
Surprisingly, we identified five patients whose tumors harbored activating mutations in other 
effectors of PI3K/mTOR signaling in addition to AKT1 E17K, a finding we confirmed in 12.5% 
of AKT1 mutant patients from an independent genomic dataset (Fig. S4). Again, the 
statistically and clinically significant longer PFS observed in these dual mutant patients, 
argues that rather than implying functional redundancy, coincident mutations in effectors of 
the same pathway may result in distinct signaling phenotypes with important therapeutic 
implications. Further biologic investigation of whether such coincident drivers further 
sensitize tumors to PI3K pathway inhibition is warranted.  
 
The analysis of cfDNA within the context of this early-phase study also yielded several 
findings with broad implications. Importantly, we observed responses in patients with 
undetectable AKT1 E17K in pretreatment cfDNA. Our findings emphasize how low tumor 
burden and insufficient shedding of cfDNA into plasma can impact detection of actionable 
biomarkers in plasma and has downstream implications for genomic screening strategies 
that rely on this technology for patient selection. We also demonstrate how cfDNA can be 
used to detect intratumoral heterogeneity unappreciated by single site tissue biopsies and 
how serial monitoring cfDNA for AKT1 mutations can serve as a surrogate for response and 
progression.  
 
Although E17K is the most common AKT1 mutation and was the focus of this study, other 
activating mutations in AKT1-3 have been identified.23 Among these, AKT1 Q79K is the 
second most recurrent hotspot mutation after E17K (Fig. S4). Of the patients with non-E17K-
mutations in this study, only those with AKT1 Q79K demonstrated tumor regressions. 
Looking beyond AKT1 E17K mutations to other mutant alleles in all three AKT isoforms, 
might therefore broaden the population of AKT-mutant patients that could benefit from AKT 
inhibitors. 
 
Despite the promising progression free survival achieved with AZD5363 in patients with 
heavily pretreated AKT1 E17K mutant breast and gynecologic cancers, the observed 
response rate was lower than with therapies targeting EGFR, ALK, ROS1, and BRAF.24-26 
Realizing the full potential of AZD5363 in AKT1-mutant cancers may require drug 
combinations. Overall, the strongest signal of activity was observed in ER+ breast cancer as 
well as endometrial cancers of the subtype associated with sensitivity to anti-estrogens. We 
also observed re-sensitization to AZD5363 following re-introduction of fulvestrant in an 
ESR1-mutant patient who had previously demonstrated resistance to both therapies, a 
finding consistent with preclinical data demonstrating reciprocal feedback between ER and 
downstream PI3K/AKT signaling.19,27 Taken together, these data provide a strong rationale 
for combining AKT inhibition with anti-estrogen therapy in estrogen-dependent AKT1-mutant 
cancers. 
 
In summary, we demonstrate that mutant AKT1 is a rational therapeutic target for AZD5363 
in diverse cancers. Unlike prior basket studies that sought to expand the indication of an 
FDA-approved drug previously studied extensively using traditional trial designs28, we show 
that a drug can be successfully studied in a mutation-specific context even when the 
mutation is consistently rare across all populations. By incorporating comprehensive tissue- 
and plasma-based correlative studies, we elucidate the multifaceted genomic basis of 
response in a manner that facilitated simultaneous translational genomic discoveries and 
clinical hypothesis validation to inform future studies. 
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FIGURE LEGENDS 
 
Figure 1: Integrated treatment outcome and genomics of AKT1 E17K solid tumors.  
Data are shown for 58 patients evaluable for response and grouped by membership in the 
AKT1 E17K-mutant breast, gynecological, and other solid tumor cohorts followed by those 
patients with non-E17K AKT1 mutations. From top to bottom: best change from baseline in 
the target lesion diameter according to RECIST version 1.1 (gradient arrows reflect not 
evaluable); duration of therapy (days) and cross over to combination AZD5363 and 
fulvestrant; and genomic annotation from pre-treatment tumor tissue or cfDNA sequencing. 
All genes in the mutational heatmap, including AKT1, reflect results from pre-treatment 
centrally-determined genomic data rather than local testing. Twelve patients enrolled lacked 
genomic data (track: Genomic Data). Individual mutations are shown as annotated in the 
accompanying legend and subclonality was determined as described in the Supplementary 
Appendix. Individual annotation tracks annotate the cancer type, best response, the 
detection of AKT1 E17K by ddPCR in baseline plasma samples, and the existence of pre-
treatment genomic data from either tumor tissue or cfDNA sequencing. 
 
Figure 2: Non-invasive monitoring of treatment response in cfDNA.  
a. Imaging at baseline and 6 weeks after treatment initiation indicate a response (in red) to 
AZD5363 in an E17K-mutant ER-positive HER2-negative breast cancer that is confirmed 
molecularly with an initial decrease in, and persistently low levels of, the AKT1 E17K burden 
in cfDNA. b. Tumor burden, indicated by a >50% decrease in AKT1 E17K mutant allele 
fraction in circulating cfDNA, was evident in all but one patient (95.5%) by day 11 of cycle 1 
of treatment, but did not correlate with outcome as measured by a duration on therapy of 
greater than 12 weeks (left). Data are shown for 23 patients with longitudinal cfDNA samples 
collected throughout treatment and who were positive for AKT1 E17K by ddPCR at baseline. 
c. A decline of circulating AKT1 E17K of >50% at day 21 compared to pretreatment was 
correlated with response to AKT inhibition (HR=0.1603; p-value = 0.00194, log-rank). d. In 
evaluable patients (see Supplementary Appendix), cfDNA progression (rise of AKT1 E17K 
allele fraction of >50% above nadir) preceded radiographic progression by a median of 42 
days (range: 0-113 days) Each line is a patient, all cfDNA collection time-points (grey dots) 
are shown normalized to the date of RECIST progression and the gray arrow is the start of 
therapy. Green filled circles correspond to the time-point of cfDNA progression as defined 
above and the red line indicates median lead time of cfDNA progression relative to 
radiological progression (green box is the 95% CI of lead times). The bottom-most patient 
had a radiological progression without AKT1 E17K rise in cfDNA. e. Shown are multi-lesion 
tissue and cfDNA sequencing results (left) and the longitudinal profile of circulating AKT1 
E17K and ESR1 D538G over the course of AZD5363 monotherapy as well as AZD5363 and 
fulvestrant combination therapy (right). Following initiation of combination therapy, the 
patient achieved a decline in circulating AKT1 E17K and ESR1 D538G, blood tumor 
markers, and a minor radiographic response lasting 8 months. 
 
Figure 3: Clonality of the sensitizing biomarker. 
a. For 37 patients with sufficient baseline sequencing data, AKT1 E17K mutant allele 
frequency is shown (orange filled circle) as is the median allele frequency of all somatic 
mutations detected in each patient (horizontal line; vertical line is the median absolute 
deviation) from pre-treatment tumor tissue or cfDNA sequencing. Patients with focal 
amplification of AKT1 E17K are indicated as red triangles, while those possessing subclonal 
AKT1 E17K are shown as blue triangles. Patients are grouped as having a heterozygous 
AKT1 E17K (left) and those possessing high mutant allele fraction (right). b. Schematic of 
the acquisition of AKT1 E17K (red line) mutant allele imbalance in this study cohort, 
beginning from a heterozygous mutation in a diploid genome and chromosome 14 (leftmost; 
maternal and paternal chromosomes are indicated). Allelic imbalance in the form of CN-LOH 
that duplicates the mutant allele (top) and can be followed by other serial genetic changes 
including genomic gains and whole-genome duplication (WGD) or either heterozygous loss 
of the WT copy (bottom left) or whole-chromosome or more focal gains of the mutant allele 
(see also Fig. S1-2). c. AKT1 E17K mutant allele imbalance by any of the mechanisms 
described in panel (b) is associated with improved PFS in response to AKT inhibition 
(median PFS of 8.2 versus 4.1 months, respectively; HR = 0.41, p=0.04). d. A patient with 
an ovarian granulosa cell tumor received AZD5363 for 8 months and achieved a best 
response of 24% tumor regression (right pelvic tumor regression shown, yellow), a notable 
response that was far greater than would have been predicted on the basis of the frequency 
of the sensitizing AKT1 mutation. e. Sequencing of eight metastatic sites sampled prior to 
therapy revealed that whereas the earliest arising lesions were clonal (FOXL2 and TERT), 
the AKT1 mutation was variably subclonal across the lesions and was present at highest 
cellular fraction (67%, subclonal) in the right pelvic tumor that achieved the best response to 
AZD5363 therapy (labeled E in panel d). f. The presence of coincident activating mutations 
in either up- or downstream effectors of PI3K/mTOR signaling in AKT1 E17K-mutant tumors 
was associated with improved PFS (median not reached versus 4.3 months without such 
lesions, HR=0.21, p=0.045). 
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TABLES 
 
Table 1: Patient demographics and baseline disease characteristics. 
 
  Patient cohort 
ER+ Breast Gynecological Other Total 
N 20 18 20 58 
Median age (range), years 57 (38–71) 63 (46–71) 57 (31–77) 59 (31–77) 
Gender, n (%)        
Male 0 - 5 (25) 5 (8.6) 
Female 20 (100) 18 (100) 15 (75) 53 (91.4) 
WHO performance status
[a]
, n (%)        
0 10 (50) 9 (50) 8 (40) 27 (46.6) 
1 10 (50) 9 (50) 12 (60) 31 (53.4) 
Primary tumor site, n (%)        
ER+ Breast 20 (100) -  20 (34.5) 
Triple Negative Breast   6 (30) 6 (6.2) 
Uterus - 8 (44.4) - 8 (13.8) 
Ovary and fallopian tubes - 7 (38.9) - 7 (12) 
Cervix - 3 (16.7) - 3 (5.2) 
Lung - - 3 (15) 3 (5.2) 
Prostate - - 3 (15) 3 (5.2) 
Colon - - 2 (10) 2 (3.4) 
Other - - 6 (30)[b] 6 (10.3) 
Median Prior Lines of Systemic 
Therapy (range) 
7 (3-14) 2.5 (1-10) 4 (1-12) 5 (1-14) 
AKT1 mutation status
[c]
, n (%)        
E17K 20 (100) 14 (77.8) 17 (85) 52 (89.7) 
Other
[d] 0 3 (16.7) 3 (15) 5(8.6) 
Not detected 0 1 (5.6) 0 1 (1.7) 
 
All patients in the full analysis set received at least one dose of AZD5363. [a] 0, fully active; 1, 
restricted in physically strenuous activity. [b] Bladder (n=1), stomach (n=1), thyroid (n=1), other (n=3). 
[c] Determined by local laboratories at baseline. [d] F35L, Q79K (x2), T34N, and V201A. WHO, World 
Health Organization. 
  
Table 2: Adverse events. Shown here are the adverse events occurring in greater than 
10% of patients overall, and of grade ≥3 severity occurring in two or more patients. 
 
  Patients (N=58) 
AE, n (%) All grades Grade ≥3 
Any AE (irrespective of causality) 58⇞ (100) 41 (70.7) 
Any AE (causally related)* 53 (91.4) 30 (51.7) 
AE by preferred term (irrespective of causality) 
Diarrhea 45 (77.6) 10 (17.2) 
Nausea 30 (51.7) 1 (1.7) 
Fatigue 23 (39.7) 2 (3.4) 
Vomiting 23 (39.7) 2 (3.4) 
Hyperglycemia 22 (37.9) 14 (24.1) 
Rash maculopapular 18 (31) 9 (15.5) 
Abdominal pain 14 (24.1) 1 (1.7) 
Decreased appetite 14 (24.1) 0 
Pyrexia 11 (19) 0 
Dizziness 10 (17.2) 1 (1.7) 
Back pain 9 (15.5) 0 
Cough 9 (15.5) 0 
Dry mouth 9 (15.5) 0 
Headache 9 (15.5) 1 (1.7) 
Pain in extremity 9 (15.5) 3 (5.2) 
Aspartate aminotransferase increased 8 (13.8) 2 (3.4) 
Alanine aminotransferase increased 5 (8.6) 3 (5.2) 
Edema peripheral 8 (13.8) 0 
Stomatitis 8 (13.8) 1 (1.7) 
Constipation 7 (12.1) 0 
Hypertension 7 (12.1) 2 (3.4) 
Nasal congestion 7 (12.1) 0 
Pruritus 7 (12.1) 1 (1.7) 
Blood creatinine increased 6 (10.3) 1 (1.7) 
Dry skin 6 (10.3) 0 
Hypokalemia 6 (10.3) 0 
Micturition urgency 6 (10.3) 0 
Myalgia 6 (10.3) 0 
Urinary tract infection 5 (8.6) 2 (3.4) 
Blood alkaline phosphatase increased 4 (6.9) 2 (3.4) 
Dehydration 3 (5.2) 2 (3.4) 
Sepsis 2 (3.4) 2 (3.4) 
Small intestinal obstruction 2 (3.4) 2 (3.4) 
 
All patients in the safety analysis set received at least one dose of AZD5363. A patient can have one 
or more preferred terms reported. Table includes AEs with an onset date on or after the date of first 
dose and up to and including 28 days following the date of last dose of study medication. At the time 
of data-cut, six patients (10.3%) had un-coded AEs, out of which two patients (3.4%) had un-coded 
AEs of grade 3 severity. *As assessed by the investigator. AE, adverse event. ⇞Includes one patient 
mistakenly enrolled without an AKT1 mutation, included in safety but not efficacy analysis set. 
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